Hyloris Pharmaceuticals SA
Biopharma company reformulating existing medications to address unmet medical needs.
HYL | BR
Overview
Corporate Details
- ISIN(s):
- BE0974363955
- LEI:
- 875500LZIWS7QEQE0I73
- Country:
- Belgium
- Address:
- Boulevard de Patience et Beaujonc 3, 4000 Liège
- Website:
- https://hyloris.com/
- Sector:
- Manufacturing
Description
Hyloris Pharmaceuticals SA is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address unmet medical needs. The company's strategy centers on reformulating and repurposing established drugs to create value-added medicines for patients, healthcare professionals, and payors. By utilizing established regulatory pathways, such as the FDA's 505(b)(2) process, Hyloris aims to reduce development timelines, costs, and risks. The company has built a broad, patented portfolio of product candidates. Its commercialized products include Sotalol IV for the treatment of atrial fibrillation and Maxigesic® IV, a non-opioid for post-operative pain. In addition to its core focus, Hyloris also develops and commercializes high-barrier generic products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-19 00:07 |
PR Hyloris Governance Update EN.pdf
|
English | 146.2 KB | ||
| 2025-11-19 00:07 |
PR Hyloris Governance Update FR.pdf
|
French | 185.3 KB | ||
| 2025-11-14 00:07 |
PR Aspirin IV Positive Clinical Trial Results EN.pdf
|
English | 187.7 KB | ||
| 2025-11-14 00:07 |
PR Aspirin IV Positive Clinical Trial Results FR.pdf
|
French | 157.6 KB | ||
| 2025-10-28 07:00 |
PressRelease_Hyloris_Orion_TXA_RTU_Europe_EN.pdf
|
English | 195.0 KB | ||
| 2025-10-28 07:00 |
PressRelease_Hyloris_Orion_TXA_RTU_Europe_FR.pdf
|
French | 181.0 KB | ||
| 2025-10-27 07:00 |
PR Iron IV for China_EN.pdf
|
English | 201.1 KB | ||
| 2025-10-27 07:00 |
PR Iron IV for China_FR.pdf
|
French | 251.9 KB | ||
| 2025-09-25 00:07 |
PR Half Year Results 2025_EN final.pdf
|
English | 392.0 KB | ||
| 2025-09-25 00:07 |
PR Half Year Results 2025_FR final.pdf
|
French | 317.6 KB | ||
| 2025-09-25 00:07 |
PR Half Year Results 2025_EN final.pdf
|
English | 392.0 KB | ||
| 2025-09-25 00:07 |
PR Half Year Results 2025_FR final.pdf
|
French | 317.6 KB | ||
| 2025-09-25 00:07 |
2025 06 30 Hyloris HY report_EN final.pdf
|
English | 1.3 MB | ||
| 2025-09-25 00:07 |
2025 06 30 Hyloris HY report_FR final.pdf
|
French | 978.2 KB | ||
| 2025-08-22 07:00 |
Press Release Hyloris Signs XTRAZA Licensing Agreement with HUONS.pdf
|
English | 206.8 KB |
Automate Your Workflow. Get a real-time feed of all Hyloris Pharmaceuticals SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Hyloris Pharmaceuticals SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Hyloris Pharmaceuticals SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-13 | Aichhorn Dietmar | Executive member | Buy | 12,500 | 144,375.00 EUR |
| 2023-06-13 | Vandebroek Jean-Luc | Executive member | Buy | 6,000 | 69,300.00 EUR |
| 2022-04-14 | Van der Elst Koenraad | Executive member | Sell | 3,312 | 56,466.40 EUR |
| 2022-03-22 | Aichhorn Dietmar | Executive member | Buy | 20,000 | 347,000.00 EUR |
| 2022-03-22 | Vandebroek Jean-Luc | Board | Buy | 3,000 | 52,050.00 EUR |
Peer Companies
